OSE Immunotherapeutics
ISIN: FR0012127173 | Ticker: OSE | LEI: 969500HIUWVGY6NZSM05
Country: France
OSE Immunotherapeutics is an integrated biotechnology company focused on developing and partnering therapies to control the immune system for immuno-oncology and autoimmune diseases.
Based in Nantes (Head Office) and Paris, OSE Immunotherapeutics has 70 employees and is listed on Euronext Paris.
2016
Served areaWorldwide
Headcount70
Headquarters22 Boulevard Benoni Goullin, 44200 Nantes – France
| Line item in (eur) | 01.01.2020 | 01.01.2021 | 01.01.2022 |
|---|---|---|---|
| Assets | N/A | 96,973,000.00 | 101,876,000.00 |
| Noncurrent Assets | N/A | 57,141,000.00 | 57,670,000.00 |
| Property Plant And Equipment | N/A | 947,000.00 | 926,000.00 |
| Intangible Assets Other Than Goodwill | N/A | 52,600,000.00 | 51,122,000.00 |
| Deferred Tax Assets | N/A | 165,000.00 | 173,000.00 |
| Current Assets | N/A | 39,832,000.00 | 44,206,000.00 |
| Current Trade Receivables | N/A | 1,074,000.00 | 772,000.00 |
| Cash and cash equivalents | 25,842,000.00 | 29,368,000.00 | 33,579,000.00 |
| Shortterm Deposits Classified As Cash Equivalents | N/A | N/A | 1,000.00 |
| Other Current Assets | N/A | 9,390,000.00 | 9,854,000.00 |
| Equity And Liabilities | N/A | 96,973,000.00 | 101,876,000.00 |
| Equity | 58,536,000.00 | 61,364,000.00 | 47,890,000.00 |
| Issued Capital | N/A | 3,597,000.00 | 3,705,000.00 |
| Share Premium | N/A | 65,449,000.00 | 65,605,000.00 |
| Treasury Shares | N/A | 93,000.00 | 160,000.00 |
| Noncurrent Liabilities | N/A | 21,481,000.00 | 37,224,000.00 |
| Noncurrent Provisions | N/A | 531,000.00 | 710,000.00 |
| Deferred Tax Liabilities | N/A | 2,080,000.00 | 1,748,000.00 |
| Longterm Borrowings | N/A | 16,552,000.00 | 30,801,000.00 |
| Current Liabilities | N/A | 14,128,000.00 | 16,761,000.00 |
| Trade And Other Current Payables To Trade Suppliers | N/A | 10,286,000.00 | 9,607,000.00 |
| Current Payables On Social Security And Taxes Other Than Income Tax | N/A | 2,108,000.00 | 3,724,000.00 |
| Current Tax Liabilities Current | N/A | 2,000.00 | 14,000.00 |
| Other Current Liabilities | N/A | 1,088,000.00 | 1,050,000.00 |
| Current Borrowings And Current Portion Of Noncurrent Borrowings | N/A | 50,000.00 | 1,611,000.00 |
| Line item in (eur) | 01.01.2020/ 01.01.2021 |
01.01.2021/ 01.01.2022 |
|---|---|---|
| Revenue | 10,432,000.00 | 26,306,000.00 |
| Other Revenue | 13,000.00 | 0.00 |
| Revenue From Contracts With Customers | 10,418,000.00 | 26,306,000.00 |
| Expense From Sharebased Payment Transactions With Employees | 2,283,000.00 | 3,773,000.00 |
| Profit Loss From Operating Activities | -18,989,000.00 | -16,625,000.00 |
| Finance Income | 31,000.00 | 267,000.00 |
| Finance Costs | 288,000.00 | 856,000.00 |
| Profit Loss Before Tax | -19,246,000.00 | -17,213,000.00 |
| Income Tax Expense Continuing Operations | -2,692,000.00 | -364,000.00 |
| Profit (loss) | -16,555,000.00 | -16,850,000.00 |
| Profit Loss Attributable To Owners Of Parent | -16,555,000.00 | -16,850,000.00 |
| Line item in (eur) | 01.01.2020 | 01.01.2021 | 01.01.2022 |
|---|---|---|---|
| Profit (loss) | N/A | -16,555,000.00 | -16,850,000.00 |
| Adjustments For Income Tax Expense | N/A | -2,692,000.00 | -364,000.00 |
| Adjustments For Increase Decrease In Trade Account Payable | N/A | N/A | 679,000.00 |
| Adjustments For Depreciation And Amortisation Expense | N/A | 273,000.00 | 1,970,000.00 |
| Adjustments For Provisions | N/A | 0.00 | 289,000.00 |
| Adjustments For Sharebased Payments | N/A | 1,787,000.00 | 2,944,000.00 |
| Cash Flows From Used In Operations | N/A | -16,306,000.00 | -10,612,000.00 |
| Income Taxes Paid Refund Classified As Operating Activities | N/A | 50,000.00 | 0.00 |
| Cash Flows From Used In Operating Activities | N/A | -19,550,000.00 | -9,919,000.00 |
| Cash Flows From Used In Investing Activities | N/A | -504,000.00 | -827,000.00 |
| Proceeds From Issuing Shares | N/A | 18,630,000.00 | 265,000.00 |
| Proceeds From Borrowings Classified As Financing Activities | N/A | 6,960,000.00 | 15,281,000.00 |
| Repayments Of Borrowings Classified As Financing Activities | N/A | 325,000.00 | 40,000.00 |
| Payments Of Lease Liabilities Classified As Financing Activities | N/A | 482,000.00 | 549,000.00 |
| Cash Flows From Used In Financing Activities | N/A | 23,580,000.00 | 14,957,000.00 |
| Effect Of Exchange Rate Changes On Cash And Cash Equivalents | N/A | 0.00 | 0.00 |
| Increase (decrease) in cash and cash equivalents after effect of exchange rate changes | N/A | 3,526,000.00 | 4,211,000.00 |
| Cash and cash equivalents | 25,842,000.00 | 29,368,000.00 | 33,579,000.00 |
Please note that some sums might not add up.
FR0012127173
LEI969500HIUWVGY6NZSM05
SectorPharmaceuticals, Biotechnology & Life Sciences
IndustryKeep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.